Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?

Molecular and Cellular Endocrinology

Volumn 418, Issue , 2015, Pages 55-65

  Asrih, Mohamed ^a   Jornayvaz, François R ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Ectopic lipids; Inflammation; Insulin resistance; Metabolic syndrome; NAFLD

Indexed keywords

4 PHENYLBUTYRIC ACID; ANOREXIGENIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; ETANERCEPT; INTERLEUKIN 6; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; SALSALATE; TAUROURSODEOXYCHOLIC ACID; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; BACTEROIDES; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM STRESS; ENERGY BALANCE; FIRMICUTES; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTESTINE FLORA; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIVER BIOPSY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; WHITE ADIPOSE TISSUE; ANIMAL; LIVER; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; LIVER; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY;

EID: 84930675030     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.02.018     Document Type: Review

References (154)

1. Aguirre V., Uchida T., Yenush L., Davis R., White M.F. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem 2000, 275:9047-9054.
2. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet. Med 2006, 23:469-480.
3. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med 2002, 346:1221-1231.
4. Arumugam M., Raes J., Pelletier E., Le Paslier D., Yamada T., Mende D.R., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
5. Asrih M., Jornayvaz F.R. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J. Endocrinol 2013, 218:R25-R36.
6. Asrih M., Jornayvaz F.R. Diets and nonalcoholic fatty liver disease: the good and the bad. Clin. Nutr 2014, 33:186-190.
7. Athyros V.G., Mikhailidis D.P., Didangelos T.P., Giouleme O.I., Liberopoulos E.N., Karagiannis A., et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr. Med. Res. Opin 2006, 22:873-883.
8. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997, 46:1319-1327.
9. Badran M., Laher I. Obesity in Arabic-speaking countries. J. Obes 2011, 2011:686430.
10. Birkenfeld A.L., Lee H.Y., Guebre-Egziabher F., Alves T.C., Jurczak M.J., Jornayvaz F.R., et al. Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice. Cell Metab 2011, 14:184-195.
11. Birkenfeld A.L., Lee H.Y., Majumdar S., Jurczak M.J., Camporez J.P., Jornayvaz F.R., et al. Influence of the hepatic Eukaryotic Initiation Factor 2 alpha (eIF2 alpha) Endoplasmic Reticulum (ER) stress response pathway on insulin-mediated ER stress and hepatic and peripheral glucose metabolism. J. Biol. Chem 2011, 286:36163-36170.
12. Bruning J.C., Michael M.D., Winnay J.N., Hayashi T., Horsch D., Accili D., et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell 1998, 2:559-569.
13. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42:987-1000.
14. Campanati A., Ganzetti G., Di Sario A., Damiani A., Sandroni L., Rosa L., et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J. Gastroenterol 2013, 48:839-846.
15. Camporez J.P., Jornayvaz F.R., Lee H.Y., Kanda S., Guigni B.A., Kahn M., et al. Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance. Endocrinology 2013, 154:1021-1028.
16. Camporez J.P., Jornayvaz F.R., Petersen M.C., Pesta D., Guigni B.A., Serr J., et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 2013, 154:3099-3109.
17. Cantley J.L., Yoshimura T., Camporez J.P., Zhang D., Jornayvaz F.R., Kumashiro N., et al. CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:1869-1874.
18. Cao H., Maeda K., Gorgun C.Z., Kim H.J., Park S.Y., Shulman G.I., et al. Regulation of metabolic responses by adipocyte/macrophage Fatty Acid-binding proteins in leptin-deficient mice. Diabetes 2006, 55:1915-1922.
19. Cariou B., Hanf R., Lambert-Porcheron S., Zair Y., Sauvinet V., Noel B., et al. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013, 36:2923-2930.
20. Carter R., Mouralidarane A., Ray S., Soeda J., Oben J. Recent advancements in drug treatment of obesity. Clin. Med. (Northfield Il) 2012, 12:456-460.
21. Chavez A.O., Molina-Carrion M., Abdul-Ghani M.A., Folli F., Defronzo R.A., Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009, 32:1542-1546.
22. Choi S.S., Diehl A.M. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr. Opin. Lipidol 2008, 19:295-300.
23. Chugh P.K., Sharma S. Recent advances in the pathophysiology and pharmacological treatment of obesity. J. Clin. Pharm. Ther 2012, 37:525-535.
24. Contos M.J., Choudhury J., Mills A.S., Sanyal A.J. The histologic spectrum of nonalcoholic fatty liver disease. Clin. Liver Dis 2004, 8:481-500. vii.
25. Cotillard A., Kennedy S.P., Kong L.C., Prifti E., Pons N., Le Chatelier E., et al. Dietary intervention impact on gut microbial gene richness. Nature 2013, 500:585-588.
26. Cummings J.H. Short chain fatty acids in the human colon. Gut 1981, 22:763-779.
27. Czaja M.J. JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol. Metab 2010, 21:707-713.
28. de Luca C., Olefsky J.M. Inflammation and insulin resistance. FEBS Lett 2008, 582:97-105.
29. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114:842-845.
30. Dominguez H., Storgaard H., Rask-Madsen C., Steffen Hermann T., Ihlemann N., Baunbjerg Nielsen D., et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res 2005, 42:517-525.
31. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol 2011, 11:98-107.
32. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest 2005, 115:1343-1351.
33. Dushay J., Chui P.C., Gopalakrishnan G.S., Varela-Rey M., Crawley M., Fisher F.M., et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139:456-463.
34. Eguchi Y., Eguchi T., Mizuta T., Ide Y., Yasutake T., Iwakiri R., et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J. Gastroenterol 2006, 41:462-469.
35. Eslami L., Merat S., Malekzadeh R., Nasseri-Moghaddam S., Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst. Rev 2013, (12). CD008623.
36. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
37. Fessler M.B., Rudel L.L., Brown J.M. Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Curr. Opin. Lipidol 2009, 20:379-385.
38. Fisher F.M., Chui P.C., Antonellis P.J., Bina H.A., Kharitonenkov A., Flier J.S., et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010, 59:2781-2789.
39. Foltz I.N., Hu S., King C., Wu X., Yang C., Wang W., et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci. Transl. Med 2012, 4:162ra153.
40. Foster T., Budoff M.J., Saab S., Ahmadi N., Gordon C., Guerci A.D. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am. J. Gastroenterol 2011, 106:71-77.
41. Fresno M., Alvarez R., Cuesta N. Toll-like receptors, inflammation, metabolism and obesity. Arch. Physiol. Biochem 2011, 117:151-164.
42. Fruchart J.C. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. Cardiovasc. Diabetol 2013, 12:82.
43. Fullerton M.D., Galic S., Marcinko K., Sikkema S., Pulinilkunnil T., Chen Z.P., et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med 2013, 19:1649-1654.
44. Gadd V.L., Melino M., Roy S., Horsfall L., O'Rourke P., Williams M.R., et al. Portal, but not lobular, macrophages express matrix metalloproteinase-9: association with the ductular reaction and fibrosis in chronic hepatitis C. Liver Int 2013, 33:569-579.
45. Gaich G., Chien J.Y., Fu H., Glass L.C., Deeg M.A., Holland W.L., et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013, 18:333-340.
46. Gao Z., Yin J., Zhang J., Ward R.E., Martin R.J., Lefevre M., et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009, 58:1509-1517.
47. Gariani K., Philippe J., Jornayvaz F.R. Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside. Diabetes Metab 2013, 39:16-26.
48. Goldfine A.B., Silver R., Aldhahi W., Cai D., Tatro E., Lee J., et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin. Transl. Sci 2008, 1:36-43.
49. Gregor M.F., Misch E.S., Yang L., Hummasti S., Inouye K.E., Lee A.H., et al. The role of adipocyte XBP1 in metabolic regulation during lactation. Cell Rep 2013, 3:1430-1439.
50. Haffner S.M. Insulin resistance, inflammation, and the prediabetic state. Am. J. Cardiol 2003, 92:18J-26J.
51. Harrison S.A., Fincke C., Helinski D., Torgerson S., Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment. Pharmacol. Ther 2004, 20:623-628.
52. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
53. Hodge A.M., Dowse G.K., Zimmet P.Z., Collins V.R. Prevalence and secular trends in obesity in Pacific and Indian Ocean island populations. Obes. Res 1995, 3(Suppl. 2):77s-87s.
54. Hoque M.E., Doi S.A.R., Mannan M., Long K., Niessen L.W., Mamun A.A. Prevalence of overweight and obesity among children and adolescents of the Indian subcontinent: a meta-analysis. Nutr. Rev 2014, 72:541-550.
55. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
56. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol 2000, 20:1595-1599.
57. Huang J., Ishino T., Chen G., Rolzin P., Osothprarop T.F., Retting K., et al. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J. Pharmacol. Exp. Ther 2013, 346:270-280.
58. Hyogo H., Tazuma S., Arihiro K., Iwamoto K., Nabeshima Y., Inoue M., et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008, 57:1711-1718.
59. Jeong S.K., Kim Y.K., Park J.W., Shin Y.J., Kim D.S. Impact of visceral fat on the metabolic syndrome and nonalcoholic fatty liver disease. J. Korean Med. Sci 2008, 23:789-795.
60. Jiang S., Yan C., Fang Q.C., Shao M.L., Zhang Y.L., Liu Y., et al. Fibroblast growth factor 21 is regulated by the IRE1alpha-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J. Biol. Chem 2014, 289:29751-29765.
61. Jornayvaz F.R., Shulman G.I. Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance. Cell Metab 2012, 15:574-584.
62. Jornayvaz F.R., Jurczak M.J., Lee H.Y., Birkenfeld A.L., Frederick D.W., Zhang D.Y., et al. A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain. Am. J. Physiol. Endocrinol. Metab 2010, 299:E808-E815.
63. Jornayvaz F.R., Samuel V.T., Shulman G.I. The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. Annu. Rev. Nutr 2010, 30:273-290.
64. Jornayvaz F.R., Birkenfeld A.L., Jurczak M.J., Kanda S., Guigni B.A., Jiang D.C., et al. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:5748-5752.
65. Jornayvaz F.R., Lee H.Y., Jurczak M.J., Alves T.C., Guebre-Egziabher F., Guigni B.A., et al. Thyroid hormone receptor-alpha gene knockout mice are protected from diet-induced hepatic insulin resistance. Endocrinology 2012, 153:583-591.
66. Jung T.W., Choi H.Y., Lee S.Y., Hong H.C., Yang S.J., Yoo H.J., et al. Salsalate and adiponectin improve palmitate-induced insulin resistance via inhibition of selenoprotein P through the AMPK-FOXO1alpha pathway. PLoS ONE 2013, 8:e66529.
67. Jurczak M.J., Lee A.H., Jornayvaz F.R., Lee H.Y., Birkenfeld A.L., Guigni B.A., et al. Dissociation of inositol-requiring enzyme (IRE1alpha)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice. J. Biol. Chem 2012, 287:2558-2567.
68. Kagansky N., Levy S., Keter D., Rimon E., Taiba Z., Fridman Z., et al. Non-alcoholic fatty liver disease-a common and benign finding in octogenarian patients. Liver Int 2004, 24:588-594.
69. Kamada Y., Takehara T., Hayashi N. Adipocytokines and liver disease. J. Gastroenterol 2008, 43:811-822.
70. Kantartzis K., Peter A., Machicao F., Machann J., Wagner S., Konigsrainer I., et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009, 58:2616-2623.
71. Karlsson F.H., Tremaroli V., Nookaew I., Bergstrom G., Behre C.J., Fagerberg B., et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013, 498:99-103.
72. Kim H.J., Kim H.J., Lee K.E., Kim D.J., Kim S.K., Ahn C.W., et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch. Intern. Med 2004, 164:2169-2175.
73. Kim J.K., Gavrilova O., Chen Y., Reitman M.L., Shulman G.I. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J. Biol. Chem 2000, 275:8456-8460.
74. Kim J.K., Michael M.D., Previs S.F., Peroni O.D., Mauvais-Jarvis F., Neschen S., et al. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J. Clin. Invest 2000, 105:1791-1797.
75. Kim J.K., Fillmore J.J., Chen Y., Yu C., Moore I.K., Pypaert M., et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:7522-7527.
76. Konner A.C., Bruning J.C. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol. Metab 2011, 22:16-23.
77. Kootte R.S., Vrieze A., Holleman F., Dallinga-Thie G.M., Zoetendal E.G., de Vos W.M., et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes. Metab 2012, 14:112-120.
78. Kopelman P.G. Obesity as a medical problem. Nature 2000, 404:635-643.
79. Kotani K., Peroni O.D., Minokoshi Y., Boss O., Kahn B.B. GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization. J. Clin. Invest 2004, 114:1666-1675.
80. Kumashiro N., Erion D.M., Zhang D., Kahn M., Beddow S.A., Chu X., et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16381-16385.
81. Kumashiro N., Yoshimura T., Cantley J.L., Majumdar S.K., Guebre-Egziabher F., Kursawe R., et al. Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats. Hepatology 2013, 57:1763-1772.
82. Kwon Y.M., Oh S.W., Hwang S.S., Lee C., Kwon H., Chung G.E. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am. J. Gastroenterol 2012, 107:1852-1858.
83. Lanthier N., Molendi-Coste O., Horsmans Y., van Rooijen N., Cani P.D., Leclercq I.A. Kupffer cell activation is a causal factor for hepatic insulin resistance. Am. J. Physiol. Gastrointest. Liver Physiol 2010, 298:G107-G116.
84. Lee H.Y., Birkenfeld A.L., Jornayvaz F.R., Jurczak M.J., Kanda S., Popov V., et al. Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology 2011, 54:1650-1660.
85. Lee Y.K., Mazmanian S.K. Has the microbiota played a critical role in the evolution of the adaptive immune system?. Science 2010, 330:1768-1773.
86. Ley R.E., Backhed F., Turnbaugh P., Lozupone C.A., Knight R.D., Gordon J.I. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11070-11075.
87. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
88. Li H., Fang Q., Gao F., Fan J., Zhou J., Wang X., et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J. Hepatol 2010, 53:934-940.
89. Loomba R., Lutchman G., Kleiner D.E., Ricks M., Feld J.J., Borg B.B., et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther 2009, 29:172-182.
90. Lumeng C.N., DelProposto J.B., Westcott D.J., Saltiel A.R. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008, 57:3239-3246.
91. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
92. Mattace Raso G., Simeoli R., Russo R., Iacono A., Santoro A., Paciello O., et al. Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet. PLoS ONE 2013, 8:e68626.
93. McKenney R.L., Short D.K. Tipping the balance: the pathophysiology of obesity and type 2 diabetes mellitus. Surg. Clin. North Am 2011, 91:1139-1148. vii.
94. Michael M.D., Kulkarni R.N., Postic C., Previs S.F., Shulman G.I., Magnuson M.A., et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 2000, 6:87-97.
95. Mittendorfer B., Magkos F., Fabbrini E., Mohammed B.S., Klein S. Relationship between body fat mass and free fatty acid kinetics in men and women. Obesity (Silver Spring) 2009, 17:1872-1877.
96. Miura K., Seki E., Ohnishi H., Brenner D.A. Role of toll-like receptors and their downstream molecules in the development of nonalcoholic Fatty liver disease. Gastroenterol. Res. Pract 2010, 2010:362847.
97. Musaiger A.O. Nutritional status of infants and young children in the Arabian Gulf countries. J. Trop. Pediatr 1996, 42:121-124.
98. Musso G., Gambino R., Bo S., Uberti B., Biroli G., Pagano G., et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 2008, 31:562-568.
99. Musso G., Gambino R., Cassader M., Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med 2011, 43:617-649.
100. Ogden C.L., Carroll M.D., Kit B.K., Flegal K.M. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief 2012, 1-8.
101. Onat A. Metabolic syndrome: nature, therapeutic solutions and options. Expert Opin. Pharmacother 2011, 12:1887-1900.
102. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306:457-461.
103. Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.O., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313:1137-1140.
104. Ozes O.N., Akca H., Mayo L.D., Gustin J.A., Maehama T., Dixon J.E., et al. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:4640-4645.
105. Palermo A., Maggi D., Maurizi A.R., Pozzilli P., Buzzetti R. Prevention of type 2 diabetes mellitus: is it feasible?. Diabetes Metab. Res. Rev 2014, 30(Suppl. 1):4-12.
106. Pardina E., Baena-Fustegueras J.A., Catalan R., Galard R., Lecube A., Fort J.M., et al. Increased expression and activity of hepatic lipase in the liver of morbidly obese adult patients in relation to lipid content. Obes. Surg 2009, 19:894-904.
107. Park H.S., Sim S.J., Park J.Y. Effect of weight reduction on metabolic syndrome in Korean obese patients. J. Korean Med. Sci 2004, 19:202-208.
108. Pawlak M., Bauge E., Bourguet W., De Bosscher K., Lalloyer F., Tailleux A., et al. The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice. Hepatology 2014, 60:1593-1606.
109. Perry R.J., Samuel V.T., Petersen K.F., Shulman G.I. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014, 510:84-91.
110. Petersen K.F., Oral E.A., Dufour S., Befroy D., Ariyan C., Yu C., et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest 2002, 109:1345-1350.
111. Petersen K.F., Befroy D., Dufour S., Dziura J., Ariyan C., Rothman D.L., et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003, 300:1140-1142.
112. Petersen K.F., Dufour S., Feng J., Befroy D., Dziura J., Dalla Man C., et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:18273-18277.
113. Petersen K.F., Dufour S., Savage D.B., Bilz S., Solomon G., Yonemitsu S., et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12587-12594.
114. Petersen K.F., Dufour S., Hariri A., Nelson-Williams C., Foo J.N., Zhang X.M., et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med 2010, 362:1082-1089.
115. Petta S., Amato M., Cabibi D., Camma C., Di Marco V., Giordano C., et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 2010, 52:1543-1552.
116. Popkin B.M. The nutrition transition in low-income countries: an emerging crisis. Nutr. Rev 1994, 52:285-298.
117. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39:188-196.
118. Qin J., Li Y., Cai Z., Li S., Zhu J., Zhang F., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490:55-60.
119. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002, 106:286-288.
120. Reynolds K., Wildman R.P. Update on the metabolic syndrome: hypertension. Curr. Hypertens. Rep 2009, 11:150-155.
121. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet 2008, 40:1461-1465.
122. Sabapathy K., Hochedlinger K., Nam S.Y., Bauer A., Karin M., Wagner E.F. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol. Cell 2004, 15:713-725.
123. Samuel V.T., Liu Z.X., Qu X., Elder B.D., Bilz S., Befroy D., et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem 2004, 279:32345-32353.
124. Samuel V.T., Liu Z.X., Wang A., Beddow S.A., Geisler J.G., Kahn M., et al. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J. Clin. Invest 2007, 117:739-745.
125. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med 2010, 362:1675-1685.
126. Savage D.B., Murgatroyd P.R., Chatterjee V.K., O'Rahilly S. Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy. J. Clin. Endocrinol. Metab 2005, 90:1446-1452.
127. Schattenberg J.M., Singh R., Wang Y., Lefkowitch J.H., Rigoli R.M., Scherer P.E., et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006, 43:163-172.
128. Schwiertz A., Taras D., Schafer K., Beijer S., Bos N.A., Donus C., et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 2010, 18:190-195.
129. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest 2006, 116:3015-3025.
130. Shimomura I., Hammer R.E., Ikemoto S., Brown M.S., Goldstein J.L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999, 401:73-76.
131. Shiri-Sverdlov R., Wouters K., van Gorp P.J., Gijbels M.J., Noel B., Buffat L., et al. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J. Hepatol 2006, 44:732-741.
132. Simons L.A., Simons J., Friedlander Y., McCallum J. Is prediction of cardiovascular disease and all-cause mortality genuinely driven by the metabolic syndrome, and independently from its component variables? The Dubbo study. Heart Lung Circ 2011, 20:214-219.
133. Singh R., Wang Y., Xiang Y., Tanaka K.E., Gaarde W.A., Czaja M.J. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 2009, 49:87-96.
134. Sinn D.H., Gwak G.Y., Park H.N., Kim J.E., Min Y.W., Kim K.M., et al. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am. J. Gastroenterol 2012, 107:561-567.
135. Smits L.P., Bouter K.E., de Vos W.M., Borody T.J., Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013, 145:946-953.
136. So J.S., Hur K.Y., Tarrio M., Ruda V., Frank-Kamenetsky M., Fitzgerald K., et al. Silencing of lipid metabolism genes through IRE1alpha-mediated mRNA decay lowers plasma lipids in mice. Cell Metab 2012, 16:487-499.
137. Solinas G., Karin M. JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction. FASEB J. 2010, 24:2596-2611.
138. Spranger J., Kroke A., Mohlig M., Hoffmann K., Bergmann M.M., Ristow M., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52:812-817.
139. Taniguchi C.M., Emanuelli B., Kahn C.R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol 2006, 7:85-96.
140. Tarantino G., Finelli C., Colao A., Capone D., Tarantino M., Grimaldi E., et al. Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyl-transferase?. J. Transl. Med 2012, 10:50.
141. Targher G., Bertolini L., Rodella S., Lippi G., Franchini M., Zoppini G., et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008, 16:1394-1399.
142. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846.
143. Tran T.T., Yamamoto Y., Gesta S., Kahn C.R. Beneficial effects of subcutaneous fat transplantation on metabolism. Cell Metab 2008, 7:410-420.
144. Tuncman G., Hirosumi J., Solinas G., Chang L., Karin M., Hotamisligil G.S. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:10741-10746.
145. Vanni E., Bugianesi E., Kotronen A., De Minicis S., Yki-Jarvinen H., Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa?. Dig. Liver Dis 2010, 42:320-330.
146. Veniant M.M., Komorowski R., Chen P., Stanislaus S., Winters K., Hager T., et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 2012, 153:4192-4203.
147. Vrieze A., Van Nood E., Holleman F., Salojarvi J., Kootte R.S., Bartelsman J.F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143:913-916. e917.
148. Webber L., Divajeva D., Marsh T., McPherson K., Brown M., Galea G., et al. The future burden of obesity-related diseases in the 53 WHO European-Region countries and the impact of effective interventions: a modelling study. BMJ Open 2014, 4:e004787.
149. Weiss R., Taksali S.E., Dufour S., Yeckel C.W., Papademetris X., Cline G., et al. The "obese insulin-sensitive" adolescent: importance of adiponectin and lipid partitioning. J. Clin. Endocrinol. Metab 2005, 90:3731-3737.
150. Wu A.L., Kolumam G., Stawicki S., Chen Y., Li J., Zavala-Solorio J., et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci. Transl. Med 2011, 3:113ra126.
151. Wu G.D., Chen J., Hoffmann C., Bittinger K., Chen Y.Y., Keilbaugh S.A., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011, 334:105-108.
152. Xu C., Bailly-Maitre B., Reed J.C. Endoplasmic reticulum stress: cell life and death decisions. J. Clin. Invest 2005, 115:2656-2664.
153. Xu J., Lloyd D.J., Hale C., Stanislaus S., Chen M., Sivits G., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
154. Zhang X., Yeung D.C., Karpisek M., Stejskal D., Zhou Z.G., Liu F., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.